{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:58:04Z","timestamp":1778637484566,"version":"3.51.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Trastuzumab emtansine (T-DM1) is a novel therapy for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, combining the targeted action of trastuzumab with the cytotoxic effects of emtansine. Although T-DM1 has demonstrated greater efficacy and safety compared to traditional therapies, concerns about hepatotoxicity and spleen-related complications have arisen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective study of 64 HER2-positive metastatic breast cancer patients treated with T-DM1 at our institution. Patients underwent computed tomography or magnetic resonance imaging at baseline and during treatment cycles. Spleen volume, portal vein diameter, and laboratory values were compared between baseline and 12\u00a0months after T-DM1 treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Median spleen volume significantly increased from 201\u00a0cm3 (IQR, 157\u2013275) at baseline to 291\u00a0cm3 (IQR, 215\u2013420) after 12\u00a0months of T-DM1 treatment (P\u00a0&amp;lt;\u00a00.001). Spleen enlargement was observed in 87.5% of patients, while no significant alteration was detected in portal vein diameter. The change in spleen volume was positively correlated with changes in serum globulin levels, liver enzymes, and bilirubin levels, but did not impact survival outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>T-DM1 therapy in HER2-positive metastatic breast cancer leads to significant spleen enlargement and systemic biochemical changes. Future studies should focus on elucidating the long-term implications of these findings and optimizing monitoring strategies for spleen-related complications.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyae141","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T11:27:29Z","timestamp":1728559649000},"page":"100-105","source":"Crossref","is-referenced-by-count":2,"title":["Impact of trastuzumab emtansine (T-DM1) on spleen volume in patients with HER2-positive metastatic breast cancer"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4452-2076","authenticated-orcid":false,"given":"Arif","family":"Akyildiz","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University Medical School , Ankara ,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7093-2722","authenticated-orcid":false,"given":"Rashad","family":"Ismayilov","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hacettepe University Medical School , Ankara ,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5694-5527","authenticated-orcid":false,"given":"Najmaddin","family":"Abdurrahimli","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hacettepe University Medical School , Ankara ,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0628-7694","authenticated-orcid":false,"given":"Aylin","family":"Ormanci","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Hacettepe University Medical School , Ankara ,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6924-9467","authenticated-orcid":false,"given":"Deniz Can","family":"Guven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University Medical School , Ankara ,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2352-3587","authenticated-orcid":false,"given":"Murat","family":"Tuncel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Hacettepe University Medical School , Ankara ,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1732-7862","authenticated-orcid":false,"given":"Mehmet Ruhi","family":"Onur","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hacettepe University Medical School , Ankara ,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-1049","authenticated-orcid":false,"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University Medical School , Ankara ,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"2025020413015277300_ref1","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody\u2013cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res"},{"key":"2025020413015277300_ref2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1080\/0284186X.2019.1670860","article-title":"Regenerative nodular hyperplasia after T-DM1: consequences from sinusoidal endothelium damages","volume":"59","author":"Benguerfi","year":"2020","journal-title":"Acta Oncol"},{"key":"2025020413015277300_ref3","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-10-0644","article-title":"Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules","volume":"9","author":"Lopus","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2025020413015277300_ref4","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","article-title":"Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Gradishar","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2025020413015277300_ref5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2025020413015277300_ref6","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2009.26.2071","article-title":"Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer","volume":"28","author":"Krop","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025020413015277300_ref7","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"2025020413015277300_ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2018.1394454","article-title":"Efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis","volume":"17","author":"Leung","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"2025020413015277300_ref9","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025020413015277300_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100561","article-title":"Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer","volume":"7","author":"Wuerstlein","year":"2022","journal-title":"ESMO Open"},{"key":"2025020413015277300_ref11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025020413015277300_ref12","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1200\/JCO.2013.49.8543","article-title":"Nodular regenerative hyperplasia after treatment with trastuzumab emtansine","volume":"34","author":"Force","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025020413015277300_ref13","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1148\/radiol.220536","article-title":"Noncirrhotic portal hypertension after trastuzumab emtansine in HER2-positive breast cancer as determined by deep learning-measured spleen volume at CT","volume":"305","author":"Choi","year":"2022","journal-title":"Radiology"},{"key":"2025020413015277300_ref14","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2012.44.9694","article-title":"Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"31","author":"Hurvitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"2025020413015277300_ref15","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1200\/JCO.2013.54.4999","article-title":"Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis","volume":"32","author":"Di\u00e9ras","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025020413015277300_ref16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s13691-019-00392-4","article-title":"Sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine (T-DM1) in advanced breast cancer","volume":"9","author":"Fujii","year":"2020","journal-title":"Int Cancer Conf J"},{"key":"2025020413015277300_ref17","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2174\/138920012802138598","article-title":"Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism","volume":"13","author":"Shen","year":"2012","journal-title":"Curr Drug Metab"},{"key":"2025020413015277300_ref18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.taap.2013.09.003","article-title":"Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability","volume":"273","author":"Poon","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"2025020413015277300_ref19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11523-017-0477-6","article-title":"Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer","volume":"12","author":"Kosmin","year":"2017","journal-title":"Target Oncol"},{"key":"2025020413015277300_ref20","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1177\/1078155220910252","article-title":"Safety of trastuzumab after trastuzumab emtansine-induced nodular regenerative hyperplasia: a case report","volume":"26","author":"Hassan","year":"2020","journal-title":"J Oncol Pharm Pract"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/2\/100\/60629807\/hyae141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/2\/100\/60629807\/hyae141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T13:02:27Z","timestamp":1738674147000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/2\/100\/7816289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,10,10]]},"published-print":{"date-parts":[[2025,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae141","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,10,10]]}}}